The company behind the test said there were positive signs that some of the most aggressive cancers could be prevented.

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) trial of its Galleri test missed its primary endpoint.  | Grail’s shares ...

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against ...

The screening—known as a liquid biopsy—is being rolled out to around 15,000 patients with suspected lung cancer, NHS England has announced. There are also plans to expand it to advanced breast cancer ...

Another challenge facing test designers is that early detection may not necessarily save lives. A crucial factor, and ...

A controversial blood test that promises to detect multiple cancers in their early stages failed to meet a key trial endpoint ...

The NHS is currently trialling a rapid blood test designed to diagnose life-threatening conditions such as sepsis and meningitis in children. The 15-minute MeMed BV blood test can swiftly distinguish ...

A flurry of such tests that look for multiple cancers with a prick are in various stages of development. The one that is ...

The alert comes as research shows around one in two UK adults are affected by the health condition ...